![conference banner](/images/conference-banner.jpeg)
Abstract
Memantine, an aminodamantane, has recently been approved to treat moderate-to-severe Alzheimers disease in the US after over 20 years on the market in Europe for treatment of Parkinsons disease. The unique properties of Memantine allow for its selective inhibition of abnormally active NMDA receptor channels while preserving normal glutamate activity and healthy neuronal function. Recently, it has been shown that compounds such as nitroglycerin, used for years for ischemic coronary disease, can also regulate the NMDA receptor channel. Novel compounds have been synthesized in an attempt to combine these activities, in an attempt to synergistically improve upon the activities of both nitrates and aminoadamantanes. We have subjected these compounds to several laboratory tests to compare their ability to affect the function of the NMDA receptor and to dilate blood vessels. These tests provide an initial indication of which of the compounds may have enhanced activity relative to memantine. The results also provide guidance for the synthesis of additional compounds that are likely to have the properties that are being sought.
Keywords: NMDA receptor, S-nitrosothiol, Electrophysiology, memantine-binding domain, open-channel block
Current Alzheimer Research
Title: The Pharmacology of Aminoadamantane Nitrates
Volume: 3 Issue: 3
Author(s): Yuqiang Wang, Jerry Eu, Mark Washburn, Tong Gong, H.-S. Vincent Chen, W. Larrick James, Stuart A. Lipton, Jonathan S. Stamler, Gregory T. Went and Seth Porter
Affiliation:
Keywords: NMDA receptor, S-nitrosothiol, Electrophysiology, memantine-binding domain, open-channel block
Abstract: Memantine, an aminodamantane, has recently been approved to treat moderate-to-severe Alzheimers disease in the US after over 20 years on the market in Europe for treatment of Parkinsons disease. The unique properties of Memantine allow for its selective inhibition of abnormally active NMDA receptor channels while preserving normal glutamate activity and healthy neuronal function. Recently, it has been shown that compounds such as nitroglycerin, used for years for ischemic coronary disease, can also regulate the NMDA receptor channel. Novel compounds have been synthesized in an attempt to combine these activities, in an attempt to synergistically improve upon the activities of both nitrates and aminoadamantanes. We have subjected these compounds to several laboratory tests to compare their ability to affect the function of the NMDA receptor and to dilate blood vessels. These tests provide an initial indication of which of the compounds may have enhanced activity relative to memantine. The results also provide guidance for the synthesis of additional compounds that are likely to have the properties that are being sought.
Export Options
About this article
Cite this article as:
Wang Yuqiang, Eu Jerry, Washburn Mark, Gong Tong, Vincent Chen H.-S., Larrick James W., Lipton A. Stuart, Stamler S. Jonathan, Went T. Gregory and Porter Seth, The Pharmacology of Aminoadamantane Nitrates, Current Alzheimer Research 2006; 3 (3) . https://dx.doi.org/10.2174/156720506777632808
DOI https://dx.doi.org/10.2174/156720506777632808 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
Alzheimer's Disease Drug Development
Alzheimer's disease is a progressive neurodegenerative disorder that affects millions of people worldwide. Despite decades of research, no cure or disease-modifying treatment is available yet. Therefore, the need for developing effective therapies to treat Alzheimer's disease is an urgent matter. This special issue aims to provide a comprehensive overview of ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer’s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Control of Neuropathic Pain by Immune Cells and Opioids
CNS & Neurological Disorders - Drug Targets A Comprehensive Review of the Pharmacological Effects of Genus Ferula on Central Nervous System Disorders
Central Nervous System Agents in Medicinal Chemistry Breathing Generation and Potential Pharmacotherapeutic Approaches to Central Respiratory Disorders
Current Medicinal Chemistry Focusing on New Monoamine Oxidase Inhibitors: Differently Substituted Coumarins As An Interesting Scaffold
Current Topics in Medicinal Chemistry Assessing Depression in Patients with an Acute Coronary Syndrome: A Literature Review
Current Psychiatry Reviews Association Between Oxidative Stress and Altered Cholesterol Metabolism in Alzheimer’s Disease Patients
Current Alzheimer Research Heart Valve Lesions In The Antiphospholipid Syndrome
Current Rheumatology Reviews Advanced Nanomedicines for the Treatment and Diagnosis of Myocardial Infarction and Heart Failure
Current Drug Targets The Alzheimer's Disease-Related Glucose Metabolic Brain Pattern
Current Alzheimer Research Epigenetics in the Cerebrovascular System: Changing the Code without Altering the Sequence
Current Neurovascular Research Are Major Depressive Disorder and Diabetes Mellitus Amyloidogenic Conditions?
CNS & Neurological Disorders - Drug Targets Nicotinamide as a Foundation for Treating Neurodegenerative Disease and Metabolic Disorders
Current Neurovascular Research Alzheimer’s Disease-like Early-phase Brain Pathogenesis: Self-curing Amelioration of Neurodegeneration from Pro-inflammatory ‘Wounding’ to Anti-inflammatory ‘Healing’
Current Alzheimer Research Physical Activity and Urinary Incontinence in Older Adults: A Community-Based Study
Current Aging Science Clinical and Environmental Correlates of Serum BDNF: A Descriptive Study with Plausible Implications for AD Research
Current Alzheimer Research TNF-α and Ghrelin: Opposite Effects on Immune System, Metabolism and Mental Health
Protein & Peptide Letters Cognitive Impairment and Diabetes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Evidence on the New Drug Lumateperone (ITI-007) for Psychiatric and Neurological Disorders
CNS & Neurological Disorders - Drug Targets Interindividual Variability in the Efficacy of Oral Antiplatelet Drugs: Definitions, Mechanisms and Clinical Importance
Current Pharmaceutical Design Nature and Nurture in the Early-Life Origins of Metabolic Syndrome
Current Pharmaceutical Biotechnology